YBX1, as previously discussed, may also play a role in the drug resistance of breast cancer cells through promoting antiestrogen resistance, and decreasing the effectiveness of endocrine therapeutic drugs for estrogen receptor positive (ER-positive) breast cancer patients (Shibata et al., 2018). This evidence concerns the gene ESR1 and breast carcinoma.